Adamas Pharmaceuticals
ADMS
ADMS was delisted on the 23rd of November, 2021.
63 hedge funds and large institutions have $148M invested in Adamas Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 20 reducing their positions, and 11 closing their positions.
3,461% more call options, than puts
Call options by funds: $819K | Put options by funds: $23K
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
5% less repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 20
6% less funds holding
Funds holding: 67 → 63 (-4)
6% less capital invested
Capital invested by funds: $157M → $148M (-$9.8M)
36% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$5.93M |
| 2 |
Bank of Montreal
Toronto,
Ontario, Canada
|
+$1.09M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$859K |
| 4 |
ACM
Altium Capital Management
New York
|
+$750K |
| 5 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
+$728K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$5.35M |
| 2 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$1.22M |
| 3 |
Two Sigma Investments
New York
|
-$1.2M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$1.02M |
| 5 |
Two Sigma Advisers
New York
|
-$867K |
ADMS Hedge Fund Activity: Q3 2021 in Review
63 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Adamas Pharmaceuticals (ADMS) for Q3 2021, worth a combined $148M — down 6.2% from $157M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of ADMS and 7 opened new positions — a net loss of 4 holders — while 20 trimmed existing stakes and 19 added.
The largest buyer was Stonepine Capital Management, adding an estimated $5.93M. The largest seller was Point72 Asset Management, cutting an estimated $5.35M.
- 63 institutional investors held Adamas Pharmaceuticals (ADMS) as of Q3 2021, down from 67 in Q2 2021.
- Funds reported $148M of Adamas Pharmaceuticals stock for Q3 2021, down 6.2% quarter-over-quarter.
- 7 funds opened new Adamas Pharmaceuticals positions in Q3 2021 and 11 closed out, a net change of -4 holders.
- The largest Adamas Pharmaceuticals buyer in Q3 2021 was Stonepine Capital Management, an estimated $5.93M added.
- The largest Adamas Pharmaceuticals seller in Q3 2021 was Point72 Asset Management, an estimated $5.35M sold.
Based on aggregated 13F filings for Q3 2021.